IONTAS, Teva announce new antibody optimisation agreement
Teva recently halted its Ajovy clinical development.
Read More
Tag: IONTAS
UK firms link to develop ADCs for cancer
UK groups Glythera and IONTAS are working together on the development of antibody drug conjugates for difficult-to-treat cancers.
Read More
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
